The impact of vaso-occlusive crises and disease severity on quality of life and productivity among patients with sickle cell disease in the US

References

• Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4 Suppl):S512–S521.
   PubMed Web of Science ®Google Scholar
• Li X, Dao M, Lykotrafitis G, et al. Biomechanics and biorheology of red blood cells in sickle cell anemia. J Biomech. 2017;50:34–41.
   PubMed Web of Science ®Google Scholar
• Shah N, Bhor M, Xie L, et al. Sickle cell disease complications: prevalence and resource utilization. PLoS One. 2019;14(7):e0214355
   PubMed Web of Science ®Google Scholar
• Darbari DS, Wang Z, Kwak M, et al. Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study. PLoS One. 2013;8(11):e79923.
   PubMed Web of Science ®Google Scholar
• van Tuijn C-O, Schimmel M, van Beers E-O, et al. Prospective evaluation of chronic organ damage in adult sickle cell patients: a seven-year follow-up study. Am J Hematol. 2017;92(10):E584–E590.
   PubMed Web of Science ®Google Scholar
• Hartzema AG, Kauf TL, Coates TD, et al. Economic burden of sickle cell disease among children and adults. Blood. 2007;110(11):958–958.
   Web of Science ®Google Scholar
• Singh R, Jordan R, Hanlon C. Economic impact of sickle cell hospitalization. Blood. 2014;124(21):5971–5971.
   Web of Science ®Google Scholar
• Niihara Y, Macan H, Eckman J, et al. L-glutamine therapy reduces hospitalization for sickle cell anemia and sickle β-thalassemia patients at six months–a phase II randomized trial. Clin Pharmacol Biopharm. 2014;3(2):1.
   Google Scholar
• Stallworth JR, Jerrell JM, Tripathi A, et al. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. Am J Hematol. 85(10):795–797.
   PubMed Web of Science ®Google Scholar
• Wang WC, Oyeku SO, Luo Z, et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics. 2013;132(4):677–683.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–439.
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381(6):509–519.
   PubMed Web of Science ®Google Scholar
• Anie KA, Grocott H, White L, et al. Patient self-assessment of hospital pain, mood and health-related quality of life in adults with sickle cell disease. BMJ Open. 2012;2(4):e001274.
   PubMed Web of Science ®Google Scholar
• Esham KS, Rodday AM, Weidner RA, et al. Assessment of health-related quality of life in adults hospitalized with sickle cell disease vaso-occlusive crisis. Blood. 2017;130:2138.
   Web of Science ®Google Scholar
• Wilkie DJ, Johnson B, Mack AK, et al. Sickle cell disease: an opportunity for palliative care across the life span. Nurs Clin North Am. 2010;45(3):375–397.
   PubMed Web of Science ®Google Scholar
• Shafrin J, Schwartz TT, Okoro T, et al. Patient versus physician valuation of durable survival gains: implications for value framework assessments. Value in Health. 2017;20(2):217–223.
   PubMed Web of Science ®Google Scholar
• Schatz J. Brief report: academic attainment in children with sickle cell disease. J Pediatr Psychol. 2004;29(8):627–633.
   PubMed Web of Science ®Google Scholar
• Schatz J, Brown R, Pascual J, et al. Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology. 2001;56(8):1109–1111.
   PubMed Web of Science ®Google Scholar
• Rizio A, Bhor M, Lin X, et al. PRO55 the relationship between vaso-occlusive crises and work productivity impairment in patients with sickle cell disease. Value in Health. 2019;22:S345.
   Web of Science ®Google Scholar
• Sickle cell disease exacts a heavy vocational toll. Hematology News, 2018. [cited 2019 Sep 5]. https://www.mdedge.com/hematology-oncology/article/168531/anemia/sickle-cell-disease-exacts-heavy-vocational-toll.
   Google Scholar
• Lubeck D, Agodoa I, Bhakta N, et al. Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease. JAMA Netw Open. 2019;2(11):e1915374.
   PubMed Web of Science ®Google Scholar
• Rizio AA, Bhor M, Lin X, et al. The relationship between frequency and severity of vaso-occlusive crises and health-related quality of life and work productivity in adults with sickle cell disease. Qual Life Res. 2020;29(6):1515–1533.
   Web of Science ®Google Scholar
• Annual Statistical Supplement to the Social Security Bulletin, 2019. In: Administration SS, ed.
   Google Scholar
• Shah N, Beenhouwer D, Broder MS, et al. Severity classification for sickle cell disease: a RAND/UCLA modified Delphi panel. Washington (DC): American Society of Hematology; 2019.
   Google Scholar
• Association AS. American Statistical Association releases statement on statistical significance and p-values. Provides principles to improve the conduct and interpretation of quantitative science. 2016. https://www.amstat.org/asa/files/pdfs/p-valuestatement.pdf
   Google Scholar
• Sterne JA, Davey Smith G. Sifting the evidence-what's wrong with significance tests? BMJ. 2001;322(7280):226–231.
   PubMed Web of Science ®Google Scholar
• Hydrea FDA label. 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/016295Orig1s047,s048Lbl.pdf.
   Google Scholar
• FDA label for Endari. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208587s000lbl.pdf.
   Google Scholar
• Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018;379(3):226–235.
   PubMed Web of Science ®Google Scholar
• Study to evaluate the effect of voxelotor administered orally to patients with sickle cell disease (GBT_HOPE) (GBT_HOPE). https://clinicaltrials.gov/ct2/show/NCT03036813?term=voxelotor&cond=Sickle+Cell+Disease&rank=1.
   Google Scholar
• Matte A, Zorzi F, Mazzi F, et al. New therapeutic options for the treatment of sickle cell disease. Mediterr J Hematol Infect Dis. 2019;11(1):e2019002.
   PubMed Web of Science ®Google Scholar
• Powars DR, Chan LS, Hiti A, et al. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine. 2005;84(6):363–376.
   PubMed Web of Science ®Google Scholar
• Joseph GJ, Latremouille-Viau D, Sharma VK, et al. Vaso-occlusive crises and costs of sickle cell disease from a commercial payer's perspective. Washington (DC): American Society of Hematology; 2019.
   Google Scholar